Our group is looking for a post-doctoral researcher to develop methodology for the analysis of cancer epigenetics data (1 year project). We have already developed several widely used methods for cancer data analysis (http://boevalab.com/tools.html). Our research center is located in a nice central district of Paris close to Port Royal and in a walking proximity from the Luxembourg garden.
This offer provides an opportunity to work on a challenging algorithmic problem with a direct application to cancer research. The goal of the project is to formulate a strategy for the analysis of ChIP-seq signal coming from dozens of tumor samples. ChIP-seq (chromatin immunoprecipitation and sequencing) is the most commonly used technique to characterize DNA binding profiles of DNA-associated proteins: transcription factors, histone modifications and histone variants and polymerase binding.
The candidate should have computer science, mathematics, physics or bioinformatics background and have strong programming skills (C++ and (Python or R)). A doctoral degree, excellent knowledge of statistics, understanding of data analysis techniques and proficiency in English are required. Experience in bioinformatics analysis would be a plus.
Starting date: July 1, 2016 or later
To apply, please send your CV, a motivation letter in English, and the names of two references to: Valentina.Boeva [at] inserm.fr
Deadline for applications: July 30, 2016
Institute website: http://cochin.inserm.fr/institute/in...e-presentation
Group website: http://boevalab.com/
-
NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...10-30-2026, 06:46 AM -
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM